The Alzheimer's Companion Engagement (ACE) Project.

October 21, 2026 updated by: Sheria Robinson-Lane, University of Michigan

Black family caregivers of older adults with Alzheimer's disease and/or related dementias (ADRD), have an increased mortality risk related to pre-existing health conditions and stress. Targeted, culturally responsive, health interventions that help Black ADRD caregivers to effectively manage their own health and use community preferenced ways of coping, can improve caregivers' overall health, perceived ability to provide care for a person with ADRD (self-efficacy), and increases the likelihood that they will experience benefits from caregiving. This clinical trial pilot will test the feasibility of a community based intervention designed to improve health outcomes for Black family caregivers of persons with ADRD.

Study Overview

Status

Completed

Intervention / Treatment

Detailed Description

The proposed intervention is a peer-supportive and facilitator-led video teleconference program that will engage small groups of caregivers weekly over 6 weeks. Each week participants (n = 36, 2-5/group) will receive a different culturally relevant caregiving or personal health strategy to practice. During the support calls, a facilitator will provide an overview of the content covered and each participant will have the opportunity to discuss their past week and how they engaged the weekly strategy, or challenges that came up for them during the week. The format will be structured to ensure that core content is reviewed, and everyone can be equally engaged while flexible enough that caregivers can receive support in the areas they need. A battery of assessment measures will be taken at weeks 1 and 8.

Study Type

Interventional

Enrollment (Actual)

25

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Michigan
      • Ann Arbor, Michigan, United States, 48109
        • University of Michigan

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion criteria for participation are as follows:

Self-identified as Black/ African American At least 18 years old Able to speak, understand, and hear spoken English Related to, or has a close personal relationship to a person over the age of 55 that has an ADRD diagnosis or evidence of cognitive impairment Regular access to a smartphone, tablet or computer with internet access that will allow video conferencing engagement.

Provides monitoring, and assistance in activities of daily living and or other care tasks for the care recipient.

-

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Caregiver Support

All participants in all groups will receive 6 weeks of caregiving support including a weekly video/teleconference call, and handouts covering relevant educational topics)

Caregivers engage in a weekly video/teleconference support group with a skilled facilitator to discuss various strategies for managing caregiving stress, challenging behaviors, and personal self-care.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Caregiver Self-efficacy for Obtaining Respite Care
Time Frame: 6 weeks

Caregiver self-efficacy was measured using the Revised Scale for Caregiving Self-Efficacy at baseline and one week following the intervention. The scale assesses the level of confidence caregivers had in obtaining respite care, responding to disruptive behaviors, and controlling their own upsetting thoughts about caregiving, using a range of 0- 100, with 0 indicating not confident one could do the described task at all and 100 indicating certainty one could perform the described task. Outcomes report the average change from baseline.

6 weeks
Caregiver Self-Efficacy for Controlling Upsetting Thoughts
Time Frame: 6 Weeks

Caregiver self-efficacy was measured using the Revised Scale for Caregiving Self-Efficacy at baseline and one week following the intervention. The scale assesses the level of confidence caregivers had in obtaining respite care, responding to disruptive behaviors, and controlling their own upsetting thoughts about caregiving, using a range of 0- 100, with 0 indicating not confident one could do the described task at all and 100 indicating certainty one could perform the described task. Outcomes report the average change from baseline.

6 Weeks
Caregiver Self-Efficacy for Responding to Disruptive Behaviors
Time Frame: 6 Weeks

Caregiver self-efficacy was measured using the Revised Scale for Caregiving Self-Efficacy at baseline and one week following the intervention. The scale assesses the level of confidence caregivers had in obtaining respite care, responding to disruptive behaviors, and controlling their own upsetting thoughts about caregiving, using a range of 0- 100, with 0 indicating not confident one could do the described task at all and 100 indicating certainty one could perform the described task. Outcomes report the average change from baseline.

6 Weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Positive Aspects of Caregiving
Time Frame: 6 weeks

The Positive Aspects of Caregiving tool is a brief assessment measure that asks questions about caregiving experiences that made the caregiver feel good about providing care. Responses are rated from 1, disagree a lot, to 5, agree a lot. Scores range from 9 to 45 with higher scores indicating more positive experiences related to family caregiving.

6 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 6, 2025

Primary Completion (Actual)

October 22, 2025

Study Completion (Actual)

October 22, 2025

Study Registration Dates

First Submitted

April 19, 2021

First Submitted That Met QC Criteria

April 19, 2021

First Posted (Actual)

April 23, 2021

Study Record Updates

Last Update Posted (Actual)

November 13, 2026

Last Update Submitted That Met QC Criteria

October 21, 2026

Last Verified

October 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • HUM00230940
  • 1K01AG065420-01A1 (U.S. NIH Grant/Contract)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

It is anticipated that the following data will be generated and made available 1) published tables, figures, graphs, and tables of data used for making graphs; 2) published journal papers, conference papers, annual reports and the final report; and 3) educational materials resulting from intervention development. All data will conform with relevant data and terminology standards.

IPD Sharing Time Frame

No less than 5 years following the date of the project completion or the date of study publication.

IPD Sharing Access Criteria

To facilitate data sharing, project data will be made publicly available via a university-managed repository Deep Blue.

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • SAP
  • ANALYTIC_CODE
  • CSR

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe